FilingReader Intelligence
Hengrui secures multiple clinical trial approvals and filing acceptance
August 18, 2025 at 09:00 AM UTC•By FilingReader AI
Jiangsu Hengrui Medicine received clinical trial approvals for HRS-4508, SHR-A1811, Adberlimab, and Bevacizumab for advanced solid tumors.
The company's Haitrebopag ethanolamine tablets for chemotherapy-induced thrombocytopenia has been accepted for marketing approval. Both HRS-4508 and Haitrebopag are novel therapies, with Haitrebopag already approved for two other indications.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime